scholarly journals Breast Cancer Post Treatment Quality of Life

10.5772/56041 ◽  
2013 ◽  
Author(s):  
Sabina Saric
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Post Treatment ◽  
Treatment Quality

scholarly journals Attachment style and respiratory sinus arrhythmia predict post-treatment quality of life in breast cancer survivors

2014 ◽  
Vol 23 (7) ◽  
pp. 820-826 ◽  
Author(s):  
Christopher P. Fagundes ◽  
Lisa M. Jaremka ◽  
William B. Malarkey ◽  
Janice K. Kiecolt-Glaser
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Survivors ◽  
Attachment Style ◽  
Respiratory Sinus Arrhythmia ◽  
Breast Cancer Survivors ◽  
Post Treatment ◽  
Treatment Quality ◽  
Sinus Arrhythmia

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

1998 ◽  
Vol 16 (7) ◽  
pp. 2382-2391 ◽  
Author(s):  
J H Fetting ◽  
R Gray ◽  
D L Fairclough ◽  
T J Smith ◽  
K A Margolin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Survival Rate ◽  
Dose Intensity ◽  
Treatment Quality ◽  
Cancer Outcomes ◽  
Node Positive ◽  
Tests Of Significance ◽  
Breast Cancer Outcomes

PURPOSE The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF). The 16-week regimen features greater doxorubicin and 5-FU dose-intensity than CAF and improved scheduling of antimetabolites with sequential methotrexate and 5-FU, as well as infusion 5-FU. PATIENTS AND METHODS A total of 646 node-positive, receptor-negative patients were randomly assigned to receive either the 1 6-week regimen or six cycles of CAF. Breast cancer outcomes included recurrence as well as disease-free and overall survival. Toxicity was evaluated by the Common Toxicity Criteria (CTC). Treatment-related quality of life was assessed by the Breast Chemotherapy Questionnaire (BCQ) before, during, and 4 months after treatment in 163 patients. The trial was designed to use one-sided tests of significance for power calculations, but is now reported with both one-sided and the traditional two-sided tests of significance. RESULTS At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided). The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided). CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity, whereas the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity. There were three treatment-related deaths with CAF but none with the 16-week regimen. During treatment, quality of life declined significantly more with the 16-week regimen than CAF, but by 4 months posttreatment, there was no difference. CONCLUSION The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life. The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule. It should probably not be tested further, but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.

The effect on quality of life via bio-mimetic hormone replacement therapy for breast cancer patients.

2017 ◽  
Vol 35 (7_suppl) ◽  
pp. 113-113
Author(s):  
TS Wiley ◽  
Jason T. Haraldsen
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Well Being ◽  
Post Treatment ◽  
Breast Cancer Patients ◽  
Long Term Study

113 Background: Many treatments for breast cancer block the estrogen receptors to reduce the risk of relapse. However, this treatment results in massive changes to the normal hormonal milieu. When the normal rhythmic hormonal patterns are disrupted, either through treatment or normal menopause, women typically experience a multitude of harsh symptoms with little affect on relapse rate. We set out to examine and evaluate the effects of estrogen (E2) and progesterone (P4) treatments via a bio-mimetic bio-identical hormone replacement therapy (BBHRT). We theorized, through the analysis of physiological and clinical literature, that the use BBHRT in the normal physiological pattern of reproductive women will lead to an increase of overall well-being and better quality of life for post-treatment and menopausal women, but does not increase their risk of breast cancer. Methods: E2 and P4 control over 9,000 different gene products and a disruption of these processes can lead to an increase in illnesses of aging including cancer. Through an evaluation of current literature, we theorize that a BBHRT approach utilizing E2 and P4 in a bio-mimetic manner to restore a woman’s body to normal hormonal levels can be achieved through twice-daily transdermal applications of hormonal creams with peaks in serum levels on days 12 and 21. The proposed method uses compounded, bio-identical hormones dosed to mimic the female reproductive cycle. Results: While this is a proposed clinical study, it is expected that women will experience resolution of menopausal and post-treatment symptoms, including better sleep, decreased migraines and incontinence, increased focus, and increased libido. By restoring the normal hormonal rhythm, it is anticipated that the body’s natural response elements will help restore both quality of life and well being, while also protecting from possible relapse. Conclusions: We propose a method to provide better quality of life and well being for women through BHRT that combines the use of E2 and P4 in a manner that mimics a woman’s normal reproductive levels. While a small long-term study of this method has shown promising results, we conclude that further, most detailed studies are still needed.

Mindfulness and Quality of Life in Cancer Survivors: The Mediating Role of Self-Kindness and Alexithymia

2016 ◽  
Vol 38 (4) ◽  
pp. 346-359 ◽  
Author(s):  
Allison M. Forti ◽  
Craig S. Cashwell ◽  
Robert Henson
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Post Treatment ◽  
Significant Variance ◽  
Mediating Role ◽  
The Relationship

The purpose of this study was to understand the relationship among mindfulness, self-kindness, alexithymia and quality of life in post-treatment breast cancer survivors and to examine whether self-kindness and alexithymia mediate the relationship between mindfulness and quality of life. Results suggested that the overall model accounted for significant variance in quality of life and that alexithymia partially mediated the relationship between mindfulness and quality of life. Implications for practice and further research are discussed.

Sign in / Sign up

Export Citation Format

Share Document